EPISODE · Apr 30, 2012 · 7 MIN
A New Day Dawning for Hodgkin Lymphoma?
from Journal of Clinical Oncology (JCO) Podcast
This podcast describes a phase 2 trial brentuximab vedotin in patients with Hodgkin lymphoma that has recurred after autologous hematopoietic stem cell transplantation. The podcast discusses the rationale for the trial, response to therapy, and associated toxicities. Future application of brentuximab vedotin to CD30+ malignancies is considered as well.
Embed this episode
NOW PLAYING
A New Day Dawning for Hodgkin Lymphoma?
0:00
7:48
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of Journal of Clinical Oncology (JCO) Podcast?
This episode is 7 minutes long.
When was this Journal of Clinical Oncology (JCO) Podcast episode published?
This episode was published on April 30, 2012.
Can I download this Journal of Clinical Oncology (JCO) Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!